Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7772
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases ; day:6 ; month:5 ; year:2017 ; pages:1-10
International journal of clinical oncology ; (6.5.2017), 1-10
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Uemura, Hiroji
- Beteiligte Personen und Organisationen
-
Uemura, Hirotsugu
Matsubara, Nobuaki
Kinuya, Seigo
Hosono, Makoto
Yajima, Yoko
Doi, Toshihiko
SpringerLink (Online service)
- DOI
-
10.1007/s10147-017-1130-1
- URN
-
urn:nbn:de:1111-201705192466
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Uemura, Hiroji
- Uemura, Hirotsugu
- Matsubara, Nobuaki
- Kinuya, Seigo
- Hosono, Makoto
- Yajima, Yoko
- Doi, Toshihiko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223